This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Randomized Controlled Trial

. 2008 Mar 22;371(9617):961-3.

doi: 10.1016/S0140-6736(08)60428-6.

Tocilizumab for rheumatoid and juvenile idiopathic arthritis

Affiliations

PMID: 18358909
DOI: 10.1016/S0140-6736(08)60428-6

Randomized Controlled Trial

Tocilizumab for rheumatoid and juvenile idiopathic arthritis

Tim Bongartz. Lancet. 2008.

. 2008 Mar 22;371(9617):961-3.

doi: 10.1016/S0140-6736(08)60428-6.

Author

Affiliation

¹ Department of Internal Medicine and Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. bongartz.tim@mayo.edu

PMID: 18358909
DOI: 10.1016/S0140-6736(08)60428-6

No abstract available

PubMed Disclaimer

Comment on

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R; OPTION Investigators. Smolen JS, et al. Lancet. 2008 Mar 22;371(9617):987-97. doi: 10.1016/S0140-6736(08)60453-5. Lancet. 2008. PMID: 18358926 Clinical Trial.
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T. Yokota S, et al. Lancet. 2008 Mar 22;371(9617):998-1006. doi: 10.1016/S0140-6736(08)60454-7. Lancet. 2008. PMID: 18358927 Clinical Trial.

Similar articles

Tocilizumab for systemic juvenile idiopathic arthritis.
Hagino N, Yamaguchi K, Ohara Y. Hagino N, et al. N Engl J Med. 2013 Mar 28;368(13):1256. doi: 10.1056/NEJMc1301017. N Engl J Med. 2013. PMID: 23534567 No abstract available.
Tocilizumab for systemic juvenile idiopathic arthritis.
De Benedetti F. De Benedetti F. N Engl J Med. 2013 Mar 28;368(13):1256-7. doi: 10.1056/NEJMc1301017. N Engl J Med. 2013. PMID: 23534566 No abstract available.
A new era in the treatment of systemic juvenile idiopathic arthritis.
Sandborg C, Mellins ED. Sandborg C, et al. N Engl J Med. 2012 Dec 20;367(25):2439-40. doi: 10.1056/NEJMe1212640. N Engl J Med. 2012. PMID: 23252530 No abstract available.
Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis.
Yokota S, Kishimoto T. Yokota S, et al. Expert Rev Clin Immunol. 2010 Sep;6(5):735-43. doi: 10.1586/eci.10.41. Expert Rev Clin Immunol. 2010. PMID: 20828281 Review.
Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
Zhang X, Morcos PN, Saito T, Terao K. Zhang X, et al. Expert Rev Clin Pharmacol. 2013 Mar;6(2):123-37. doi: 10.1586/ecp.13.1. Expert Rev Clin Pharmacol. 2013. PMID: 23473591 Review.

See all similar articles

Cited by

Preclinical and clinical role of interleukin-6 in the development of delayed cerebral vasospasm and neuronal cell death after subarachnoid hemorrhage: towards a potential target therapy?
Croci DM, Sivanrupan S, Wanderer S, Agnoletto GJ, Chiappini A, Grüter BE, Andereggen L, Mariani L, Taussky P, Marbacher S. Croci DM, et al. Neurosurg Rev. 2022 Feb;45(1):395-403. doi: 10.1007/s10143-021-01628-9. Epub 2021 Aug 27. Neurosurg Rev. 2022. PMID: 34448990 Free PMC article. Review.
Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients.
Chen J, Zheng DX, Yu XJ, Sun HW, Xu YT, Zhang YJ, Xu J. Chen J, et al. Oncoimmunology. 2019 Aug 15;8(11):e1652540. doi: 10.1080/2162402X.2019.1652540. eCollection 2019. Oncoimmunology. 2019. PMID: 31646099 Free PMC article.
Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy.
Dayakar A, Chandrasekaran S, Kuchipudi SV, Kalangi SK. Dayakar A, et al. Front Immunol. 2019 Apr 5;10:670. doi: 10.3389/fimmu.2019.00670. eCollection 2019. Front Immunol. 2019. PMID: 31024534 Free PMC article. Review.
Recent advances in neutralizing the IL-6 pathway in arthritis.
Malemud CJ. Malemud CJ. Open Access Rheumatol. 2009 Oct 5;1:133-150. doi: 10.2147/oarrr.s6266. eCollection 2009. Open Access Rheumatol. 2009. PMID: 27789987 Free PMC article. Review.
Anti-proliferative action of IL-6R-targeted antibody tocilizumab for non-small cell lung cancer cells.
Kim NH, Kim SK, Kim DS, Zhang D, Park JA, Yi H, Kim JS, Shin HC. Kim NH, et al. Oncol Lett. 2015 May;9(5):2283-2288. doi: 10.3892/ol.2015.3019. Epub 2015 Mar 9. Oncol Lett. 2015. PMID: 26137057 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information